Pharmaceutical Executive_ 12th Annual Pharm Exec 50
14
Pharmaceutical Executive: 12th Annual Pharm Exec 50 http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM] You print copies on the honor system; we trust that you will only make up to 5. Need more than 5 copies? See other print options. Revenue Distribution of Top 50 Global Pharma Sales by Region Print Email Post Republish May 1, 2011 12th Annual Pharm Exec 50 By Jerry Cacciotti,Patrick Clinton Will the recent wave of megamergers and a slow revival of biotech financing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profits and placating a restive new breed of payers and the ever-expectant patient The Pharm Exec 50 ranks the world's largest pharmaceutical companies by global sales of prescription drugs—a key indicator of market change. After last year's storm of activity, the 50 set a more placid pace, as major players worked on integrating blockbuster mergers and licked their wounds after the latest round of Phase III failures. Late-phase problems are nothing new, and drug candidates can come back from them, but there was something particularly heartbreaking about the recent crop of dead ends, given the huge unmet medical need associated with these therapies: Pfizer's Dimebon and Lilly's Semagacestat for Alzheimer's, Merck's vicriviroc for HIV, and Roche's ocrelizumab for rheumatoid arthritis, to name just a few. Change was most visible on the macro level. The list of the top 10 companies was shaken up a bit, with Novartis passing Sanofi-Aventis to move into second place, and Merck jumping from seventh to fourth. It was also the first year the top company crossed the $50 billion mark in sales of prescription drugs—as Pfizer, fueled by its acquisition of Wyeth, grew from $45.4 billion in Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues to place a premium on size and scale: This was the first year that it took $2 billion in Rx revenues to join the 50. As recently as 10 years ago, you could make the list with revenues of only $500 million. Overall, the 50 accounted for $593.4 billion in human prescription drug sales in 2010. That represents an increase of nearly 8 percent from 2009, when the total was $550.5 billion. But among the top 10, there was slightly better growth. This year's group grew its Rx revenues from $319.4 billion in fiscal 2009 to $352.5 last year—an increase of over 10 percent. A good percentage of that growth was fueled by mergers and acquisitions. In addition to Pfizer and its 29 percent increase, big gainers included Merck (58 percent growth after its merger with Schering SPONSORS (Ads will not print)
-
Upload
babyracoon -
Category
Documents
-
view
180 -
download
1
Transcript of Pharmaceutical Executive_ 12th Annual Pharm Exec 50
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
You print copies on the honor system; we trust that you will only make up to 5.
Need more than 5 copies? See other print options.
Revenue Distribution of Top 50
Global Pharma Sales by Region
Print Email Post Republish
May 1, 2011
12th Annual Pharm Exec 50By Jerry Cacciotti,Patrick Clinton
Will the recent wave of megamergers and a slow revival of biotech financing beenough to counter a looming storm surge of patent expirations? US health reformis the next big game-changer, as companies seek a balance between earningprofits and placating a restive new breed of payers and the ever-expectantpatient
The Pharm Exec 50 ranks the world's largest pharmaceuticalcompanies by global sales of prescription drugs—a key indicator ofmarket change. After last year's storm of activity, the 50 set a moreplacid pace, as major players worked on integrating blockbustermergers and licked their wounds after the latest round of Phase IIIfailures. Late-phase problems are nothing new, and drug candidatescan come back from them, but there was something particularly
heartbreaking about the recent crop of dead ends, given the huge unmet medicalneed associated with these therapies: Pfizer's Dimebon and Lilly's Semagacestatfor Alzheimer's, Merck's vicriviroc for HIV, and Roche's ocrelizumab forrheumatoid arthritis, to name just a few.
Change was most visible on the macro level.The list of the top 10 companies was shaken upa bit, with Novartis passing Sanofi-Aventis tomove into second place, and Merck jumpingfrom seventh to fourth. It was also the first yearthe top company crossed the $50 billion mark insales of prescription drugs—as Pfizer, fueled byits acquisition of Wyeth, grew from $45.4 billionin Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues toplace a premium on size and scale: This was the first year that it took $2 billionin Rx revenues to join the 50. As recently as 10 years ago, you could make thelist with revenues of only $500 million.
Overall, the 50 accounted for $593.4 billion in humanprescription drug sales in 2010. That represents an increaseof nearly 8 percent from 2009, when the total was $550.5billion. But among the top 10, there was slightly better growth.This year's group grew its Rx revenues from $319.4 billion infiscal 2009 to $352.5 last year—an increase of over 10percent.
A good percentage of thatgrowth was fueled bymergers and acquisitions. Inaddition to Pfizer and its 29
percent increase, big gainers included Merck (58percent growth after its merger with Schering
SPONSORS
(Ads will not print)
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Top 25 US Pharma Products by Sales
Top 20 Therapeutic Classes by Spending
Top 20 Therapeutic Classes by Prescriptions
Plough) and Abbott (up nearly 28 percent in the wake of its acquisitions ofSolvay and Piramal). But the biggest single-year bump came at a much smallercompany: The Irish firm Warner Chilcott last year acquired the pharmaceuticalbusiness of Procter & Gamble, including the billion-dollar drug Actonel, andraised its Rx revenues a whopping 111 percent to $2.9 billion.
Looming over the year—and the decade—is theshadow of US healthcare reform. Many inpharma feel they have dodged the bullet of newregulation and stand to gain as a projected 30million previously uninsured Americans finallyobtain insurance coverage for healthcare. Butthe Patient Protection and Affordable Care Actis not the end of the discussion—it's more likethe beginning of an avalanche. The economicforces it sets in motion today will be playing out
for payers, patients, providers, and pharma for the foreseeable future, changingthe way care is delivered and paid for, creating numerous business threats, but,with luck, ending up with the possibility of getting a better alignment betweenhelping the patient and earning a profit.
Top 25 Corporations by U.S. Sales
Top 25 Corporations by Prescriptions
Top 25 U.S. Pharma Products byPrescriptions
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Top US Patent Expiries
Top 20 Global Therapy Classes by Sales
Top 20 Leading Global Products by Sales
The Top 10 Year In Review
1. Pfizer President and CEO Jeff Kindler retired, succeeded by Ian C. Read.George Lorch elected Non-Executive Chairman of the Board. Sutent approved inEU for treatment of pancreatic neuro-endocrine tumors. Launched Prevnar 13, avaccine against 13 strains of pneumococcal diseases in infants and youngchildren. Also has 118 products in the R&D pipeline and had 1,300 clinical trialsin 2010.
2. Novartis Completed purchase of Alcon from Nestlé for $38.5 billion.Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenezas Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals inthe US, Europe, and Japan, with 147 products in development. Tasigna wasapproved in the US, the EU, Japan, and Switzerland for patients with newlydiagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML), a form of blood cancer. Menveo (vaccine against meningococcal disease)launched in the US, EU, and parts of Latin America and Asia. Sandoz launchedgeneric enoxaparin, its most successful launch to date, and acquired OrielTherapeutics.
3. Sanofi-Aventis Initiated acquisition of Genzyme for $16.6 billion(completed in April) and finished acquisition of OTC company Chattem. Begancollaboration programs with Harvard and Columbia Universities and a researchalliance with Scripps Genomic Medicine. Jevtana approved in US for second-linetreatment of metastatic hormone-refractory prostate cancer.
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
4. Merck Elected Kenneth Frazier CEO. Bought Inspire for $430 million.Rotateq vaccine awarded top honor at Prix Galien USA 2010. MerckBioVentures entered into an alliance with Parexel for biosimilar development.Signed commercialization agreement with Lundbeck for Sycrest and a letter ofmutual intent with China's Sinopharm. Pipeline has more than 20 late-stagecandidates. Licensed oral mTOR inhibitor for multiple cancers from Ariad. Oralhepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.
5. Roche Rituxan approved in US as first-line treatment for chronic lymphocyticleukemia (CLL) and relapsed/refractory CLL. Tarceva approved in US and EU forfirst-line treatment of non-small-cell lung cancer after chemotherapy. FDArejected use of Avastin as a treatment for metastatic breast cancer; Roche hasrequested a hearing to appeal this decision. Daniel O'Day appointed COO of thePharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaudappointed Head of Roche Pharma Research and Early Development.
6. GlaxoSmithKline Benlysta (belimumab, the first new lupus treatment in 60years) approved by FDA in March. Six products in total approved by US and EU;seven more filed with regulators. Malaria vaccine in Phase III trials in Africa, with30 other late-stage assets. Julian Heslop retired as CFO, succeeded by SimonDingemans. Patents for active ingredients in Seretide/Advair expired.
7. AstraZeneca Crestor substance patent upheld in US court. Approvalsinclude Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique(atherothrombotic event prevention) in EU. Kombiglyze XR, the only once-dailydose of DPP4/metformin, developed with Bristol-Myers Squibb, also approved inUS. Nine molecules in Phase III trials or submitted for regulatory approval, withanother 92 projects in development. Completed deal with Rigel for developmentof fostamatinib (rheumatoid arthritis).
8. Johnson & Johnson Completed tender offer for Crucell N.V. in February2011; acquired 98.93 percent of shares. Products under regulatory reviewinclude: Rivaroxoban for stroke prevention in patients with atrial fibrillation (US),Telaprevir for hepatitis C (US and EU), Abiraterone acetate for metastaticadvanced prostate (US and EU), and rilpivirine for HIV. Eight more candidatesplanned for regulatory submission from 2011 to 2013.
9. Eli Lilly Completed acquisition of Alnara and Avid Radiopharmaceuticals.Launched statin Livalo in the US with partner Kowa. Has 68 molecules indevelopment. Several monoclonal antibodies for cancer in late-stagedevelopment. Phase III candidates include Necitumumab for non-small-cell lungcancer and Ramucirumab for metastatic breast and gastric cancers. Signedcommercialization deal with Acrux for newly approved experimental testosteronesolution Axiron.
10. Abbott The year was marked by acquisitions, including the pharmaceuticalbusiness of Solvay for $6.1 billion plus milestones, and Piramal Healthcare'sHealthcare Solutions business, a leader in the Indian branded generics market,for $2.2 billion in cash, plus $1.6 billion in annual payments through 2014.Additional acquisitions included Advanced Medical Optics, STARLIMSTechnologies (informatics), and the remaining shares of Facet Biotech.
About the Authors Jerry Cacciotti is a Partner in Oliver Wyman's Health and Life SciencesPractice. He can be reached at [email protected][[email protected]]
Patrick Clinton is Marketing Director in the Health & Life Sciences practice ofOliver Wyman. He can be reached at [email protected][[email protected]]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Revenue Distribution of Top 50
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Global Pharma Sales by Region
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Pharmaceutical Executive: 12th Annual Pharm Exec 50
http://license.icopyright.net/user/viewFreeUse.act?fuid=MTI5NTYyNzc%3D[5/27/2011 1:34:10 PM]
Top 25 US Pharma Products by Sales
Top 20 Therapeutic Classes by Spending Top 20 Therapeutic Classes by Prescriptions Top 25 Corporations by U.S. Sales Top 25 Corporations by Prescriptions Top 25 U.S. Pharma Products by Prescriptions
Top US Patent ExpiriesTop 20 Global Therapy Classes by SalesTop 20 Leading Global Products by Sales
Ads by Google Windows Server License MS SQL Server Cal
